Friday, November 14, 2003

OncoLink's daily online reports from the Chemotherapy Foundation Symposium in New York City on November 12-14, 2003. For those users interested in obtaining CME for this program, please enter the CME portion of this course.

New York City

Bevacizumab (Avastin) in Advanced Prostate Cancer Faculty Disclosure: Joel Picus, MDThis presentation by Dr. Picus discusses the use of bevacizumab in the treatment of prostate cancer which has not been approved by the FDA. Presenter: Joel Picus, MD Affiliation: Washington University School of...
CT-2103 (Xyotax): Phase II Trial of a Polyglutamated Paclitaxel Conjugate in Advanced NSCLC Faculty Disclosure: Howard A. Burris, III, MDbr>In this presentation Dr. Burris discusses the use of CT-2103 for the treatment of lung cancer which has not been approved by the FDA. Presenter: Howard A. Burris, III, MD Affiliation: Sarah Cannon...
Erlotinib (Tarceva) and Bevacizumab (Avastin): Combination Therapy for NSCLC Faculty Disclosure: Roy S. Herbst, MDThis presentation by Dr. Herbst will discuss the use of bevacizumab and erlotinib in the treatment of lung cancer which has not been approved by the FDA. Presenter: Roy S. Herbst, MD Affiliation: M.D. Anderson...
Erythropoietic Agents: Recent Clinical Data Over the last several decades anemia management has evolved. Use of transfusion is now limited to symptomatic severe anemia. The use of stem cell growth factors to prevent the occurrence of anemia has become the norm. Epoetin alpha (Procrit) and...
IImpact and Therapeutic Implications of Anemia in Lung Cancer Presenter: Corey Langer, MD Affiliation: Fox Chase Cancer Center, Philadelphia, PA Anemia in cancer patients is a common problem with a multifactorial etiology. It is well recognized that the presence of malignancy is associated with a blunted...
Molecular Prediction of Response and Survival in NSCLC Presenter: Gerold Bepler, MD PhD Affiliation: H. Lee Moffitt Cancer Center Pharmacogenomic research offers the potential for improving upon the results of conventional treatments in managing lung cancer. Currently, the choice of treatment...
Neutropenia Control: Optimising Therapeutic Gains Neutropenia is often the dose limiting toxicity in chemotherapy treatment. A great advance came with filgrastin, decreasing the incidence of febrile neutropenia and hospitalizations in patients given the injections following chemotherapy. The use...
Novel Approaches in Stage III NSCLC Presenter: Hak Choy, MD Affiliation: Vanderbilt University School of Medicine The top cause of cancer-related mortality in the United States among both males and females remains lung cancer. Typically, as many as 80% of cases are non-small cell...
Optimized Schedule of Weekly Paclitaxel Alone and With Carboplatin: Elderly Advanced NSCLC Patients Presenter: Chandra Belani, MD Affiliation: University of Pittsburgh Lung cancer continues to be the leading cause of cancer death in the United States, with approximately 80% of cases being NSCLC. The overall survival and median survival time in...
Tumor Markers and the Early Detection of Lung Cancer Presenter: James Mulshine, MD Affiliation: National Cancer Institute Lung cancer has recently outstripped coronary artery disease as the leading cause of smoking related death in the USA. One half of new lung cancers are diagnosed in former...